<DOC>
	<DOCNO>NCT00109642</DOCNO>
	<brief_summary>This study examine role brain chemical call norepinephrine thinking , decision-making , emotional processing . After norepinephrine release brain cell , bind another brain cell 's receptor . Some receptor bind call alpha-2 adrenergic receptor . This study use medicine call yohimbine guanfacine look function norepinephrine brain bind alpha-2 adrenergic receptor . Yohimbine increase norepinephrine 's function guanfacine decrease function . Healthy volunteer 20 50 year age heart disease , high blood pressure , psychiatric illness , serious medical condition allergic lactose may eligible study . Candidates screen medical psychiatric history , physical examination , neuropsychological testing , blood urine test electrocardiogram . Women screen urine pregnancy test . Participants give pill yohimbine , guanfacine , placebo undergo follow test procedure : - Blood pressure heart rate measurement : Blood pressure heart rate measure medication take several time . - Blood draw : Blood drawn medicine take 90 minute measure level norepinephrine hormone cortisol . - Neurocognitive testing : Participants neurocognitive task computer 90 minute . The task involve look picture word screen respond accord instruction give . - Magnetic resonance imaging ( MRI ) : Patients may undergo neurocognitive test MRIs . This test use strong magnetic field radio wave show change brain activity . The subject lie table slide narrow cylinder ( MRI scanner ) . Images brain obtain subject performs computer task .</brief_summary>
	<brief_title>The Role Norepinephrine Emotional Processing</brief_title>
	<detailed_description>An understanding role specific neurotransmitter neurocognitive function mediate emotional processing essential understanding treatment mood anxiety disorder . One disorder , currently regard untreatable , psychopathy . Psychopathy link noradrenergic amygdala disturbance . However , understand functional significance noradrenergic system human remain infancy . The goal protocol use target noradrenergic manipulation ( yohimbine guanfacine ) conjunction specific neurocognitive neuroimaging paradigm consider role norepinephrine reward punishment processing . In particular , wish evaluate hypothesis increase norepinephrine level follow administration yohimbine lead enhance formation process stimulus-reward stimulus-punishment association , decrease norepinephrine level follow administration guanfacine reduce formation process stimulus-reward stimulus-punishment association . In addition , aim examine hypothesis increase norepinephrine level lead increase neural response amygdala either formation , processing , stimulus-reinforcement association .</detailed_description>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>INCLUSION CRITERIA : Age : Participants male female , 2050 year age . IQ : IQ , measure 4 subscales Wechsler Adult Intelligence ScaleRevised ( WAISR ) , must great 80 . Medication status : No current use psychotropic medication benzodiazepine . EXCLUSION CRITERIA : Because factor psychiatric disease , CNS disease , influence functional brain activity , factor exclusionary : Psychiatric History : Participants assess use DSMIV criterion via standardized psychiatric interview conduct trained examiner ( SCID ) . All participant free current past major affective disorder , psychotic disorder , substance dependence , anorexia , somatoform disorder , anxiety disorder exception specific phobia . Severe acute chronic medical illness ( e.g . cardiac disease , diabetes , epilepsy ) . CNS disease : Known history brain abnormality ( e.g. , neoplasms , subarachnoid cyst ) , cerebrovascular disease , infectious disease ( e.g. , abscess ) , central nervous system disease , history head trauma result persistent neurologic deficit loss consciousness great 3 minute . Currently regular medication would interfere study result . This include alpha beta adrenergic medication , antihypertensive medication , glucocorticoid mineralocorticoid medication , medication cause sedation stimulation . For example , current use tylenol ibuprofen permit , current use benadryl methylphenidate . Use oral contraceptive pill permit . Currently breast feed pregnant ( documented pregnancy test screening day challenge study ) . Additional exclusion criterion fMRI study : Metal electronic object : Metal plate , certain type dental brace , cardiac pacemaker , etc. , sensitive electromagnetic field contraindicate MRI scan . Claustrophobia : participant question potential discomfort enclose space , MRI scanner . Body weight reduce likelihood significant orthostasis guanfacine , participant must weigh 60kg great . Those weigh less 60 kg exclude .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 8, 2009</verification_date>
	<keyword>Amygdala</keyword>
	<keyword>Orbitofrontal Cortex</keyword>
	<keyword>Yohimbine</keyword>
	<keyword>Emotion</keyword>
	<keyword>Guanfacine</keyword>
	<keyword>Norepinephrine</keyword>
	<keyword>Healthy Volunteer</keyword>
</DOC>